Radically different
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here.
Good morning. Big news: I’ve convinced at least one other STAT staffer to re-read “The Odyssey” with me ahead of the movie this summer. Starting today, that means we’ll read three books (chapters), or about 1,500 lines, per week for the next eight weeks. Care to join us?
“Pull over!” I order my brother one sunny February afternoon. Our target is in sight: a gaggle of Canada geese, pecking at grass near the dog park. As I approach, tiptoeing over their grayish-white poop, I notice that one bird wears a white cuff around its slender black neck. It’s a GPS tracker—part of a new tech-centered campaign to drive the geese out of my hometown of Foster City, California.
About 300 geese live in this sleepy Bay Area suburb, equal to nearly 1% of our human population—and some say this town isn’t big enough for the both of us. Goose poop notoriously blanketed our middle school’s lawn, and the birds have hassled residents for generations. My own grandmother remembers when geese took over her garage for five whole minutes before waddling out. She says, “I wanted to kill them, but I thought I’d get in trouble.”
Indeed, that idea doesn’t fly here. City officials backed out of a previous plan to kill 100 geese following uproar from local environmentalists. Still, the poop creates a public health hazard; the birds need to go.
So the city paid nearly $400,000—roughly $1,300 per goose—to Wildlife Innovations, a company that resolves conflicts between humans and wildlife, to haze the geese with gadgets. The company’s approach is “basically, making the geese less comfortable,” Dan Biteman, head of the goose management plan and senior wildlife biologist at Wildlife Innovations, tells me.
The need for such conflict resolution is on the rise as land development collides with changes in animal behavior. Though overpopulation of Canada geese is a national nuisance in the US, such tensions also surface with other species in this country and elsewhere, including grizzlies on the Montana prairies, coyotes on San Francisco streets, and savanna elephants in Tanzania parks.
So the people whose job it is to deal with recalcitrant critters are bringing on the gadgets.
Back in Foster City, I spot a black camera mounted to a tree trunk at Gull Park by the lagoon. They’re in seven parks around town, programmed to snap photos every 15 minutes and transmit them back to Wildlife Innovations HQ. If they detect geese, a biologist immediately drives over to disperse the birds. One team member uses devices like lasers or drones; another brings along a goose-hating border collie named Rocky.
As a special measure, staff deploy the “Goosinator,” a small, remote-controlled neon-orange pontoon boat with a fearsome dog-like mouth painted on its bow, meant to evoke geese’s fear of coyotes and bright colors. It comes with attachable wheels and can zoom around on land or water to chase birds away. Biteman tells me the company is thinking about mounting speakers on trees and flying drones that will screech the calls of goose predators like red-tailed hawks or golden eagles.
The company received federal permits required by the Migratory Bird Treaty Act to stick GPS trackers on 10 geese, too. This way, staff can surveil the geese and research their behavior and movements.
At local goose hangouts, signs that look like “Wanted” posters alert the public to the new plan. As I watch some culprits graze (and defecate) on a church lawn, I think to myself: Enjoy it while it lasts.
Annika Hom is an award-winning independent journalist. She’s written for National Geographic, Wired, and more.
Fluorescent probes have reshaped how biologists study living systems, making it possible to watch viruses invade cells, follow the cell’s internal waste‑disposal machinery, and track the signaling events that fuel tumor growth. Yet even with decades of innovation, a fundamental limitation has persisted: most fluorescent nanobody probes glow whether or not they are bound to their targets. That constant background haze can blur the very molecular details researchers are trying to resolve.
A new imaging platform developed by scientists at Albert Einstein College of Medicine and the Salk Institute for Biological Studies aims to eliminate that problem entirely. The technology, described in Nature Methods in a paper titled “Synthetic multicolor antigen-stabilizable nanobody platform for intersectional labelling and functional imaging,” uses engineered fluorescent nanobodies that become brightly fluorescent only when they bind their intended protein targets. These “on‑demand” probes, known as VIS‑Fbs (visible-spectrum target-stabilizable fluorescent nanobodies), illuminate proteins inside living cells and animals with far greater clarity than conventional tools.
“The key advantage of our approach is that the signal appears only where the target protein is present,” said Vladislav Verkhusha, PhD, co‑corresponding author and professor of genetics at Einstein. “That eliminates the background glow that has long limited the precision of intracellular imaging.” His collaborator, Axel Nimmerjahn, PhD, professor and the Françoise Gilot‑Salk Chair at Salk, added, “This work establishes a versatile platform for imaging proteins with high specificity and minimal background. It opens new opportunities to study how molecular and cellular processes unfold in real time across diverse biological systems.”
Nanobodies have become increasingly valuable for live‑cell imaging because they can be engineered to bind specific proteins with high affinity. But their ongoing fluorescence has remained a stubborn obstacle. The VIS‑Fb design solves this by making the probes unstable when unbound; they rapidly degrade unless they encounter their target. Binding stabilizes the nanobody and triggers bright fluorescence, reducing background noise by as much as 100‑fold. The team also created VIS‑Fbs that span nearly the entire visible spectrum, from blue to far red, enabling simultaneous tracking of multiple proteins or cellular processes within the same cell.
The researchers developed a modular engineering platform, instead of a single probe, capable of generating VIS‑Fbs for a wide range of targets and experimental needs. They integrated more than 20 fluorescent proteins and biosensors into multiple nanobody scaffolds, creating a flexible system that supports multicolor imaging, light‑switchable variants for precise temporal control, and functional readouts of ions and metabolites. This allows the probes not only to show where proteins are but also to show what those proteins are doing in real time. According to first author Natalia Barykina, PhD, “The VIS‑Fb approach allows us to identify and track specific cell populations in living organisms based on the proteins they express, rather than just their location.”
In mice, VIS‑Fbs allowed for high‑contrast imaging of neuronal and astrocyte activity during behavior. In zebrafish embryos, the probes captured rapid developmental changes and responses to drugs that modulate signaling pathways. “Our results show that this imaging platform offers a much clearer and more precise view of how proteins behave inside living systems,” Verkhusha said. “It opens the door to studying complex biological processes, such as cell signaling, development, and disease progression, in new ways.”
The post Antigen‑Stabilized Nanobody Probes Enable On‑Demand, Multicolor Protein Imaging appeared first on GEN – Genetic Engineering and Biotechnology News.
A deeply phenotyped healthy Hong Kong cohort reveals age- and sex-dependent immune, clinical, and lifestyle variation, highlighting population-specific differences and the need to extend systems immunology frameworks beyond European ancestry.
Hang et al. identify an out-of-frame CBX3::ALK fusion in metastatic melanoma that generates functional ALK isoforms through alternative translation start sites. This study demonstrates that rare noncanonical out-of-frame fusions can be oncogenic and therapeutically actionable, highlighting an analytic blind spot in current gene fusion detection pipelines.
SAN DIEGO — Revolution Medicines is already cooking up the next iteration of RAS inhibiting drugs.
At the American Association of Cancer Research annual meeting here, the company is the talk of the town for the clinical trial success of daraxonrasib, its next generation targeted therapy, in advanced pancreatic cancer. And while the company presented more data on that drug Tuesday, showing promising first line and combination data on daraxonrasib, scientists also showed in another session intriguing preclinical data on a completely new compound that may represent what comes after the current lineup.
That drug, currently called RM-055, is what RevMed CEO Mark Goldsmith is calling an entirely “novel class of catalytic inhibitors.” These are targeted therapies that not only block the RAS signaling that drives cancer, but molecularly turn the cancer protein off.
A one-time, personalized cell therapy from Kyverna Therapeutics improved mobility and reduced disabilities in patients with stiff person syndrome, a rare, neurological autoimmune disorder, according to study results presented Tuesday.
Kyverna intends to submit the treatment to the Food and Drug Administration by the middle of the year. If approved, it would become the first treatment for stiff person syndrome and the first personalized CAR-T therapy for an autoimmune disease of any kind to reach the market.
Currently, CAR-T treatments are approved only for blood cancers, but using engineered T cells to deplete B cells — essentially performing an immune system reset inside a patient — has pushed a growing number of biotech companies to shift their CAR-T focus to autoimmune diseases.